Inuzuka Hiroyuki, Fukushima Hidefumi, Shaik Shavali, Liu Pengda, Lau Alan W, Wei Wenyi
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Oncotarget. 2011 Mar;2(3):239-44. doi: 10.18632/oncotarget.242.
Loss of the Fbw7 tumor suppressor is common in diverse human cancer types, including T-Cell Acute Lymphoblastic Leukemia (T-ALL), although the mechanistic basis of its anti-oncogenic activity remains largely unclear. We recently reported that SCFFbw7 regulates cellular apoptosis by controlling the ubiquitination and destruction of the pro-survival protein, Mcl-1, in a GSK3 phosphorylation-dependent manner. We found that human T-ALL cell lines displayed a close relationship between Fbw7 loss and Mcl-1 overexpression. More interestingly, T-ALL cell lines that are deficient in Fbw7 are particularly sensitive to sorafenib, a multi-kinase inhibitor that has been demonstrated to reduce Mcl-1 expression through an unknown mechanism. On the other hand, Fbw7-deficient T-ALL cell lines are much more resistant to the Bcl-2 antagonist, ABT-737. Furthermore, reconstitution of Fbw7 or depletion of Mcl-1 in Fbw7-deficient cells restores ABT-737 sensitivity, suggesting that elevated Mcl-1 expression is important for Fbw7-deficient cells to evade apoptosis. Therefore, our work provides a novel molecular mechanism for the tumor suppression function of Fbw7. Furthermore, it provides the rationale for targeted usage of Mcl-1 antagonists to treat Fbw7-deficient T-ALL patients.
Fbw7肿瘤抑制因子的缺失在多种人类癌症类型中很常见,包括T细胞急性淋巴细胞白血病(T-ALL),尽管其抗癌活性的机制基础在很大程度上仍不清楚。我们最近报道,SCFFbw7通过以GSK3磷酸化依赖性方式控制促生存蛋白Mcl-1的泛素化和降解来调节细胞凋亡。我们发现人类T-ALL细胞系在Fbw7缺失和Mcl-1过表达之间表现出密切关系。更有趣的是,缺乏Fbw7的T-ALL细胞系对索拉非尼特别敏感,索拉非尼是一种多激酶抑制剂,已被证明可通过未知机制降低Mcl-1表达。另一方面,缺乏Fbw7的T-ALL细胞系对Bcl-2拮抗剂ABT-737具有更强的抗性。此外,在缺乏Fbw7的细胞中重建Fbw7或耗尽Mcl-1可恢复ABT-737敏感性,这表明Mcl-1表达升高对于缺乏Fbw7的细胞逃避凋亡很重要。因此,我们的工作为Fbw7的肿瘤抑制功能提供了一种新的分子机制。此外,它为靶向使用Mcl-1拮抗剂治疗缺乏Fbw7的T-ALL患者提供了理论依据。